Erik Oliemuller

Background

About Erik Oliemuller

PhD educated life sciences consultant with over 15 years track record in oncology research and development and 3 years in life sciences strategic consulting. With my extensive experience leading scientific projects, I offer proven strategic decision-making skills to advance drug development. I thrive in dynamic environments and make impactful contributions with my technical expertise and leadership abilities. I am a passionate, curious, and honest team player, motivated by integrity and professionalism with excellent analytical and leadership skills. I am excellent at synthesizing and communicating complex scientific and clinical topics in an organized and balanced manner. In my latest role as a life sciences senior consultant, I collaborated with pharma internal teams, supporting them in strategic decision-making, ultimately helping them to advance pipeline assets to the clinic and support early launch, life cycle management (LCM) and marketing activities. I leveraged my robust background in oncology and life sciences to forge global relationships with KOLs and healthcare professionals to deliver scientific insights to advance medical strategies. With a main focus on oncology and hematology, I have performed competitive landscape assessments of innovative MoAs (Cell therapy, ADCs, T-cell engagers.) for several global clients. In addition, I participated in projects across other therapy areas, such as Type 1 Diabetes (T1D), GVHD, and rare diseases (HAE and DMD), demonstrating a great ability to learn quickly about new TAs. Additionally, I acted as the project manager and medical writer of the syndicated services Celltelligence, where I excelled in managing a team of scientific writers specialized in crafting medical newsletters on cell therapies in oncology and hematology, reaching readers in 30+ top pharma and biotech companies, and enhancing their understanding of this complex field. I have extensive experience in translational oncology in the biotech industry and highly prestigious international research centers in oncology, with a special focus on breast and lung cancer.